An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Study of AZD9829 in CD123+ Hematological Malignancies
Trial Status: active
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will
be administered intravenously as monotherapy or in combination in participants with CD123
positive hematological malignancies.
Inclusion Criteria
≥18 years of age;
CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory;
R/R AML (except APL);
R/R HR-MDS with ≥5% bone marrow blast at time of inclusion;
Had at least 1 prior line of therapy at currents histology, and have no available treatment options;
ECOG performance status of ≤ 2. The above is a summary, other inclusion criteria details may apply.
Exclusion Criteria
Active CNS leukemia;
Previous treatment with any CD123 targeting therapy;
Prior allogeneic HSCT, within 90 or cell therapy within 60 of start of therapy;
Active GVHD that requires immunosuppressive treatment within 4 weeks prior to start of AZD9829;
History of other malignancy(with certain exceptions);
Active and uncontrolled infections;
Unresolved AEs ≥2 Grade, from prior therapies. The above is a summary, other exclusion criteria details may apply .
Additional locations may be listed on ClinicalTrials.gov for NCT06179511.
